BIONDVAX PHARMA/S (NASDAQ:BVXV) Cut to “Buy” at ValuEngine

ValuEngine lowered shares of BIONDVAX PHARMA/S (NASDAQ:BVXV) from a strong-buy rating to a buy rating in a report released on Thursday, ValuEngine reports.

BVXV traded up $0.03 on Thursday, reaching $5.94. 900 shares of the company traded hands, compared to its average volume of 6,441. BIONDVAX PHARMA/S has a one year low of $3.51 and a one year high of $7.26. The firm has a fifty day moving average price of $6.08.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last announced its quarterly earnings data on Thursday, May 30th. The company reported $0.02 earnings per share for the quarter. Equities analysts predict that BIONDVAX PHARMA/S will post -0.08 EPS for the current year.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

See Also: Quiet Period Expirations

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.